Catalent Makes Two Key European Appointments in Oral Dose Manufacturing
Catalent Pharma Solutions has made two key appointments at its Schorndorf, and Eberbach, Germany, facilities.
Dr Irmgard Neuper is the new General Manager at Catalent’s Schorndorf facility, which provides large-scale, complex oral solid manufacturing with integrated analytical, development, and packaging services.
Dr Neuper joins Catalent from Sandoz, with 17 years of operating and leadership experience in Technical Operations functions in Austria, the US, Germany and Brazil, where she gained significant expertise in manufacturing, from early pharmaceutical intermediates to finished dosage forms. Her most recent role at Sandoz was as Site Head at the company’s Gerlingen, Germany, facility.
Prior to this, she served in a number of roles at Sandoz, including Global Quality Project Manager; Site Head for Solid Oral Dosage forms and Liquids in Brazil; Head of Production for Frankfurt Industrial products; and Project Manager for R&D at the Geneva, US, site.
Dr Neuper has a PhD in Agricultural Sciences and a Diploma in Engineering for Food and Biotechnology, both from University for Agricultural Sciences, Vienna.
In a second announcement, Luc Burgard will become the new General Manager of Catalent’s 360,000 sq.ft. Eberbach softgel manufacturing facility.
Mr Burgard joined Catalent in October 2011 as European Operational Excellence Leader, based in Beinheim, France, before being appointed as Operations Director at the Eberbach site in April 2013. Prior to joining Catalent, he was employed by Faurecia, a global automotive technology supplier for 9 years, working in progressively senior operational roles including the Global Leader in Engineering Methodologies.
Mr Burgard holds a Bachelor’s Degree in electronics and quality from Cergy-Pontoise University, as well as an Advanced Master’s Degree in innovative design and mathematics from the Institut National des Sciences Appliquées of Strasbourg.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance